Chloroquine and hydroxychloroquine for COVID-19: Perspectives on their failure in repurposing

Rashmi R. Shah MD, FRCP, FFPM, HonFBPhS

Pharmaceutical Consultant, Gerrards Cross, UK

Correspondence
Rashmi R. Shah, 8 Birchdale, Gerrards Cross, UK.
Email: clinical.safety@hotmail.co.uk

Abstract

What is known and Objective: Non-clinical studies suggest that chloroquine (CQ) and hydroxychloroquine (HCQ) have antiviral activities. Early clinical reports of successful HCQ-associated reduction in viral load from small studies in COVID-19 patients spurred a large number of national and international clinical trials to test their therapeutic potential. The objective of this review is to summarize the current evidence on the safety and efficacy of these two agents and to provide a perspective on why their repurposing has hitherto failed.

Methods: Published studies and rapidly emerging data were reviewed to gather evidence on safety and efficacy of CQ and HCQ in patients with COVID-19 infection or as prophylaxis. The focus is on clinically relevant efficacy endpoints and their adverse effects on QT interval.

Results and Discussion: At the doses used, the two agents, given alone or with azithromycin (AZM), are not effective in COVID-19 infection. The choice of (typically subtherapeutic) dosing regimens, influenced partly by "QT-phobia," varied widely and seems anecdotal without any pharmacologically reliable supporting clinical evidence. A substantial proportion of patients receiving CQ/HCQ/AZM regimen developed QTc interval prolongation, many with absolute QTc interval exceeding the potential proarrhythmic threshold, but very few developed proarrhythmia.

What is new and Conclusion: The strategy to repurpose CQ/HCQ to combat COVID-19 infection is overshadowed by concerns about their QT liability, resulting in choice of potentially subtherapeutic doses. Although the risk of QT-related proarrhythmia is real, it is low and manageable by careful monitoring. Recent discontinuation of HCQ from at least four large studies effectively marks the end of efforts at repurposing of CQ or HCQ for COVID-19 infection. This episode leaves behind important questions on dose selection and risk/benefit balance in repurposing drugs generally.

KEYWORDS
chloroquine, COVID-19, dose-response, hydroxychloroquine, interleukin-6, QT interval, viral infections

1 WHAT IS KNOWN AND OBJECTIVES

Repurposing old drugs for novel indications has gathered momentum over the last 2 decades in an effort to curb drug development costs and reduce time-lines to regulatory approval of drugs whose safety profile is already well known. This momentum is the result of systematic re-evaluation of many old drugs which are found in non-clinical studies to have activities at targets well beyond the ones
originally investigated. The term ‘repurposing’ has not been clearly defined but generally means the development of an out-of-patent drug for a novel pharmaco-therapeutic indication. An unsubstantiated assumption is that the safety profile of the drug is comparable across all indications, despite potential differences in drug-disease or drug-drug interactions.

Clinical examples of successful repurposing are few. Most prospective randomized clinical trials have failed to confirm expectations from non-clinical investigations or from observational prospective randomized clinical trials have failed to confirm expectations from non-clinical investigations or from observational retrospective clinical studies. Perhaps no drug illustrates this gap better than pravastatin. Statins, widely used in cardiovascular medicine, have been reported to have tissue-specific anticancer properties. LUNGSTAR, one of the largest prospective placebo-controlled studies, was carefully planned to investigate the benefits of adding pravastatin 40 mg daily to standard chemotherapy in patients with small-cell lung cancer. Pravastatin performed no better than placebo.

Chloroquine (CQ) is a synthetic analogue of quinine, a muscle-relaxant quinoline found in the bark of Cinchona tree (Cinchona officinalis). The bark extract was first used in the West to treat malaria in 1631 in Rome. Following isolation of quinine from the bark in 1820, its analogue CQ was first synthesized in 1934 and marketed as RESOCHIN®. Clinical trials showed CQ to be a highly effective anti-malarial drug, and it was introduced clinically in 1947 as treatment and prophylaxis against malaria. Subsequently, hydroxychloroquine (HCQ) was synthesized in 1946 and introduced clinically in 1955 for the same purposes under the brand name of PLAQUENIL®.

Based on earlier non-clinical evidence and the impact of ongoing COVID-19 pandemic, there has been interest in repurposing CQ and HCQ for combating this infection. The virulence, clinical outcomes and the rapid globalization of this pandemic since its origin in Wuhan (China) in December 2019 have led to unprecedented global scientific collaboration. Early release of data from scientific studies has appeared at such an extraordinary rate that it is difficult to keep pace with them. This review is a critical commentary on repurposing CQ and HCQ in combating COVID-19 infection, with particular focus on dose selection and perceived cardiotoxicity.

2 | PREVIOUS EFFORTS AT REPURPOSING CQ AND HCQ IN VIROLOGY

Chloroquine and HCQ are approved for both treatment and prophylaxis against malaria. Both have wide-ranging activities against bacteria, fungi, protozoa, parasites and viruses. Clinically, CQ is also approved for the treatment of hepatic amoebiasis.

In non-clinical studies, CQ and HCQ have shown a variety of pharmacological effects, leading to their use in other conditions. For example, based on different mechanisms of action, both are approved for use in rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and light-sensitive skin eruptions. Therefore, it could be argued that CQ and HCQ have already been repurposed for use in novel pharmaco-therapeutic indications unrelated to infections. Furthermore, CQ is reported to have antitumour activity and in November 2014, preliminary findings led the European Commission to grant CQ an orphan drug designation for the treatment of glioma.

Chloroquine and HCQ have attracted much attention for their antiviral activity. CQ was first investigated as an antiviral agent in 1963. The exact mechanism(s) of their antiviral activity is not clear but evidence suggests that 4-aminoquinolines such as CQ and HCQ have at least four mechanisms by which they may act against diverse RNA viruses and reduce the cytokine storms they generate. These are (a) inhibition of viral entry; (b) inhibition of viral release into the host cell; (c) reduction of viral infectivity; and (d) immunomodulation. They inhibit viral release into the host cell by increasing late endosomal and lysosomal pH, resulting in impaired release of the virus from the endosome or lysosome. Since the release of the virus requires a low pH, the virus is unable to release its genetic material into the cell and replicate. CQ also seems to act as a zinc ionophore that allows extracellular zinc to enter the cell and inhibit viral RNA-dependent RNA polymerase. CQ inhibits thiamine uptake but the significance of this effect in terms of its antiviral activity is unclear at present.

Not surprisingly, both drugs have been investigated for use in various viral infections and have demonstrated in vitro antiviral activity against herpes simplex virus type 1, ZIKA, HIV, MERS, SARS-CoV, HCoV-OC43, Chikungunya, hepatitis C and several other viruses. However, very few randomized clinical studies have investigated their antiviral efficacy. Rodrigo et al have summarized 13 clinical studies that investigated the efficacy of these agents in four viral infections and concluded that the benefit of either drug was either lacking or doubtful. To date, there is no evidence of CQ having successfully treated any acute viral infection in man.

3 | CURRENT EFFORTS AT REPURPOSING CQ AND HCQ FOR COVID-19 INFECTION

Chloroquine was shown in vitro to have antiviral activity against severe acute respiratory syndrome (SARS) associated coronavirus infection. Since the appearance of the current pandemic with COVID-19, a virus closely related to SARS, there has been an unparalleled resurgence of interest in the potential value of CQ and HCQ against this infection which is associated with high morbidity and mortality. This interest intensified following an endorsement of HCQ as a safe and effective prophylactic medication by US President Donald Trump despite little reliable evidence of its efficacy or safety. This endorsement was associated with an abrupt increase in the number of prescriptions for HCQ. A survey of 1197 professionals by the Heart Rhythm Society revealed substantial use of HCQ, with or without azithromycin (AZM), among the respondents in the treatment of COVID-19 patients.
3.1 | Current evidence concerning efficacy of HCQ

The pharmacokinetics of CQ and HCQ are complex but comparable. In the indications approved, their efficacy is also comparable but in animal studies, HCQ has been reported to be significantly less toxic than CQ. In humans, HCQ has also been reported to have lower retinal toxicity than CQ. Therefore, HCQ has been studied more widely than CQ, both alone and in combination with AZM, as a potential therapy against COVID-19 infection. AZM is a macrolide antibiotic reported to be immunomodulatory and antiviral. It is also reported to reduce production of pro-inflammatory cytokines such as interleukin (IL)-8, IL-6 and tumour necrosis factor (TNF)-alpha, reduce oxidative stress and modulate T-helper functions.

Among the earliest studies claiming benefits of HCQ in patients with COVID-19 were two, one each from France and China, both with significant impact on expectations of the clinical community. However, the French study that used the combination of HCQ and AZM at lower retinal toxicity than CQ. Therefore, HCQ has been studied more widely than CQ, both alone and in combination with AZM, as a potential therapy against COVID-19 infection. AZM is a macrolide antibiotic reported to be immunomodulatory and antiviral. It is also reported to reduce production of pro-inflammatory cytokines such as interleukin (IL)-8, IL-6 and tumour necrosis factor (TNF)-alpha, reduce oxidative stress and modulate T-helper functions.

The principal findings of the main representative studies, reported as of 10 July, 2020, are summarized in Table 1. A critical review of the earlier of these studies can be found elsewhere. These studies, including to date the largest RECOVERY trial, show that at the doses used, CQ or HCQ (with or without AZM) is not effective in reduction of viral load, post-exposure prophylaxis, improving survival or reducing the need for respiratory support in hospitalized patients. However, these studies varied widely in terms of design, patient populations studied, intended indications (prophylactic or curative), sample size and the severity of infection. Although the US FDA had recommended 800 mg on day 1, followed by 400 mg daily for 4-7 days for the EUA, the dosing schedules of HCQ in these studies also varied widely as shown in Table 2 in terms of loading dose (range 400-2400 mg), maintenance dose (range 400-800 mg) and duration of maintenance treatment (range 1-14 days). Four studies also reported concomitant treatment with AZM (typically 500 mg on day 1 followed by 250 mg daily for 4 days).

Critical, based on anecdotal reports of efficacy in COVID-19 infection, HCQ began to be hoarded, thereby increasing its worldwide demand and creating a shortage for its approved use in RA and SLE with potentially serious consequences for these patients. In anticipation of product shortages, the FDA also issued product-specific guidance for CQ phosphate and for HCQ sulphate for generic drug manufacturers.

Although the study was retracted within 2 weeks of its (initial online) publication on 22 May 2020, it is relevant to consider here the multinational registry analysis by Mehra et al because, like its earlier French counterpart, it further demonstrates the adverse impact of premature application of inadequately validated data. This study of CQ and HCQ, with and without a macrolide, in 96,032 patients hospitalized with COVID-19, reported that each of these drug regimens was associated with decreased in-hospital survival and an increased frequency of ventricular arrhythmias. Consequently, almost immediately, the use of HCQ in the DISCOVERY and the SOLIDARITY trials was temporarily suspended. Other European governments also followed suit, dealing further blows to the hopes promoted by the US President. However, on 4 June 2020, Mehra et al retracted their study following several concerns regarding the veracity of the data and analyses. Consequently, the WHO resumed the HCQ arm of the SOLIDARITY trial. On 5 June 2020, however, the RECOVERY investigators concluded following an interim analysis that HCQ had no beneficial effect and discontinued with immediate effect enrolment of patients to the HCQ arm of the trial. During mid-June 2020, the FDA also determined that CQ and HCQ are unlikely to be effective in treating COVID-19 and revoked the EUA and the HCQ arm was once again discontinued not only from the SOLIDARITY trial but also from the ORCHID trial.
Both CQ and HCQ have serious adverse effects, particularly on cardiac repolarization that results in prolongation of the QT interval of the surface electrocardiogram (ECG). Drug-induced prolongation of QT interval is commonly due to inhibition of IKr, the principal outward current responsible for cardiac repolarization. When excessive (typically ≥ 500 ms) or in presence of other risk factors such as bradycardia or hypokalaemia, prolonged QT interval is often a precursor of potentially fatal ventricular tachyarrhythmia known as the torsade de pointes (TdP). TdP is usually self-terminating but in rare cases can degenerate into ventricular fibrillation.

Hydroxychloroquine, and to a lesser extent AZM, blocks the IKr current and their combination has a greater effect. In addition, AZM also increases peak and late sodium current, thereby further delaying cardiac repolarization. Clinically, CQ, HCQ and AZM have long been known to prolong QT interval and induce ventricular tachyarrhythmias including TdP. AZM dose-dependently increases CQ-induced QTc interval prolongation.

Early observations suggestive of efficacy of HCQ had already led to widespread off-label use of CQ and HCQ, with or without AZM, in routine clinical medicine to treat COVID-19 patients. Consequently, there was a rapid increase in the number of reports of QTc interval prolongation and serious ventricular tachyarrhythmias in association with these drugs. Gerard et al reported receiving 120 reports of cardiac adverse drug reactions in the 1 month beginning 27 March 2020. Of these, 103 (86%) were associated with HCQ alone or associated with AZM (60%). Among the 131 reported effects, there were 90 (68.7%) of QTc prolongation and 8 (6.1%) of ventricular arrhythmias as well as 8 (6.1%) of sudden or aborted deaths. Reports such as this and others led regulatory authorities to issue warnings concerning the proarrhythmic potential of these drugs when used without appropriate monitoring and outside hospital setting or clinical trials.

In the efficacy studies summarized above, ECG monitoring was undertaken in 7 studies. When monitored, QTc interval
prolongation, typically ≥60 ms increase over baseline, often led to discontinuations of the study drug; however, only 1 patient exceeded the 500 ms proarrhythmic threshold but without developing an arrhythmia. Patients with COVID-19 infection frequently have multiple risk factors for QT-related arrhythmias, including hypokalaemia, comedations with QT-prolonging potential and comorbidities. Therefore, a number of investigators undertook studies specifically to examine the cardiac safety of CQ and HCQ in COVID-19 patients.

One Brazilian study, comparing two doses of CQ together with AZM, had to prematurely discontinue the high-dose arm because of cardiac safety concerns. In this study, QTc interval > 500 ms was found in 11.1% of the low-dose cohort and 18.9% of the high-dose cohort; ventricular tachycardia in the two groups were 0 and 2, respectively. A more recent study, investigating the effect of lower doses of CQ in 95 hospitalized COVID-19 patients, reported CQ-induced QTc prolongation of ~35 ms, with 22 patients (23%) who had normal baseline values developing QTc interval > 500 ms. A small but significant increase in the QRS duration in this study possibly led to slight overestimation of CQ-induced QTc prolongation but there were no cases of TdP.

QT-related findings from five studies, investigating the QT liability of HCQ, are summarized in Table 3. The dose of HCQ used was 800 mg on day 1 followed by 400 mg daily for 4 days in three studies; and 400 mg for 10 days in one; the dosing scheme was not specified in the other. Concomitant AZM (250-500 mg for 5 days) was variously administered in all the five studies. In the study by Mercuro et al, one patient receiving the combination discontinued because of QTc prolongation (499 ms) but developed TdP 3 days later and went on develop other ventricular arrhythmias; however, this patient had other risk factors (bradycardia and use of propofol). The likelihood of prolonged QTc was reportedly greater in patients receiving concomitant loop diuretics or had a baseline QTc ≥ 450 ms.

Collectively, these five studies suggest that although a significant proportion of patients develop marked prolongation of QTc interval at the doses studied, the risk of a proarrhythmia is very small.

### 3.3 COVID-19 infection per se confers QT susceptibility

COVID-19 is a disease with high inflammatory component. IL-6 is one of the main mediators of inflammatory and immune response initiated by infection or injury. Increased levels of IL-6, found in more than half of patients with COVID-19, seem to be associated...
with inflammatory response, respiratory failure, need for mechanical ventilation and/or intubation and increased mortality. IL-6 reportedly inhibits IKr current via IL-6R and JAK pathway activation, resulting in QT interval prolongation observed in inflammatory diseases. In patients with RA, inflammatory cytokines (TNF-alpha, IL-1b, IL-6, IL-10) have been shown to positively correlate with QTc interval duration.

Administration of tocilizumab, an IL-6 inhibitor, results in marked reduction in QT interval duration in these patients. In another study, 80% of the 40 patients with TdP showed elevated CRP levels with an identifiable inflammatory disease in 18 (45%) of these cases. In these subjects, IL-6 (but not TNF-alpha and IL-1) level was ~15-20 times higher than in controls. In the inflammatory cohort, where QTc prolongation was common, CRP reduction was associated with a decrease in IL-6 level and significant QTc shortening (~22.3 ms). Thus, it may not be entirely coincidental that many patients with reported HCQ-induced QTc prolongation have higher systemic inflammatory response and be in intensive care units requiring intubation.

### 4 | DISCUSSION

Under normal circumstances, drug development is an orderly process whereby, after appropriate clinical pharmacology and dose-ranging studies, pivotal clinical trials are undertaken with an identified optimal dose to characterize a drug for its efficacy and safety during clinical use. Important among the clinical pharmacology studies are the drug-drug interaction studies which could impact safety and efficacy during routine clinical use, whereas the pivotal trials are carefully designed with specific inclusion and exclusion criteria.

Clinical trials aimed at repurposing CQ and HCQ for COVID-19 have hitherto proceeded without prior determination of a safe and effective antiviral clinical dose. In the pursuit of urgently finding an anti-COVID-19 agent, there appears to have been a lack of a systematic approach. The global scientific response, although highly collaborative in spirit, appears fragmented and disorganized. This is perhaps best illustrated by premature enthusiastic response to early studies from China and France followed by the study reported by Mehra et al. In an effort to find a therapeutic agent to fight COVID-19, a large number of clinical trials have proliferated but these trials vary widely in their design, target population and its stratification, indication, exclusion criteria, sample size, drugs and their dosing regimen, duration of therapy and study endpoints. An analysis of 201 trials registered before 26 March this year concluded that a third of these exclude clinical endpoints, almost half were designed to recruit 100 patients or less and more than 70% were open label, thus limiting their long-term usefulness. Furthermore, the roles of potential drug interactions or inflammation per se which may impact the safety (including QT liability) or efficacy have not received the attention they deserve. It is questionable if a new drug can expect to be approved these days on the basis of the study designs used hitherto for repurposing CQ or HCQ, with or without AZM, and the

### Table 3

| Study       | Patients (n) | Drugs                      | QTc ≥ 500 ms | ΔQTc ≥ 60 ms | Torsade de pointes (n) | QTc > 500 ms ECG-related discontinuations |
|-------------|--------------|----------------------------|--------------|--------------|------------------------|------------------------------------------|
| Saleh et al | 201          | CQ/HCQ ± AZM (n = 82)      | 14.9%        | 27.1%        | 1.9%                   | 2.7%                                     |
| Bessière et al | 40      | HCQ ± AZM                  | 25%          | 6%           | 33%                    | 17.5%                                    |
| Mercuro et al | 90      | HCQ ± AZM                  | 8%           | 21%          | 0%                     | 14%                                      |
| Maraj et al  | 91           | HCQ + AZM                  | 12%          | 13%          | (Not reported)         | 14%                                      |

Abbreviation: CQ, chloroquine.
quality of evidence used to support dose selection; approval can only be expected if the evidence of efficacy in a life-threatening condition is consistent, even if preliminary.

Overall evaluation of the available evidence (Table 1) shows that at the doses used, CQ or HCQ (with or without AZM) is not effective in reduction of viral load, post-exposure prophylaxis, improving survival or reducing the need for respiratory support in hospitalized patients. However, these studies were undertaken in absence of reliable information on the effective therapeutic dose or concentration of HCQ in COVID-19 patients. As shown in Table 2, the dosing schedules of HCQ have varied widely. It is also likely that the effective doses and the level of efficacy are different in subgroups of patients with different viral loads and/or severity of disease.

If HCQ was effective against COVID-19 at the doses used, it would be expected that patients with SLE receiving long-term HCQ therapy (typically 200-400 mg daily for years) will be relatively protected from COVID-19 infection (pre-exposure prophylaxis). Although it is almost impossible to compute this risk prospectively, available evidence shows that HCQ therapy at these doses does not confer protection to these patients.90-93

Pharmacokinetic modelling studies aimed at determining an optimal dose have used different approaches and have concluded with different optimal doses.81,94-96 Although their modelling study has a number of limitations, Garcia-Cremades et al95 have suggested that the half-maximal effective concentration (EC50) of HCQ was 4.7 µmol/L (~1.58 µg/mL), comparable to those reported in in vitro studies. Based on structure-activity considerations, Garcia-Cremades et al95 assumed in their modelling that CQ and HCQ are equipotent in prolonging QT interval and predicted that HCQ doses >400 mg twice daily for ≥5 days were more likely than lower dose (≤400 mg daily) regimens to rapidly decrease viral loads, reduce the proportion of patients with detectable COVID-19 infection and shorten treatment courses. HCQ course of 400-600 mg twice daily for 10 days was unlikely to be associated with clinically significant cardiac toxicity in patients without a known risk factor for QTc prolongation, whereas HCQ daily doses (>600 or 800 mg twice daily), although efficacious, were predicted to increase the risk of QTc prolongation.95 Their modelling did not permit prediction of the impact of concomitant AZM on risk of HCQ-induced QTc prolongation.

Importantly, therapeutic or cardiotoxic plasma concentrations of HCQ have not been established. If one accepts HCQ dose >400 mg twice daily for ≥5 days as the most optimal as suggested,93 the HCQ dosing regimens used in most clinical studies, except the RECOVERY trial95 and the one by Tang et al,43 were likely subtherapeutic. Furthermore, pharmacokinetics of HCQ are so complex and variable that many patients do not achieve the presumed therapeutic concentrations of >1 and <2 µg/mL.82 For example, mean HCQ concentrations following the same dosing regimen in the two French studies29-38 with contradictory efficacy findings were lower as well as much different (0.46 and 0.68 µg/mL, respectively). In the study by Million et al,44 mean (SD) concentration of HCQ on day 2 of treatment was 0.25 (0.16) µg/mL. The choice of doses was probably influenced not only by the results of various pharmacokinetic simulations but also possibly concerns on cardiotoxicity (“QT-phobia”). Interestingly, in the study by Perinel et al,82 HCQ was withdrawn in two patients due to QT interval prolongation (381-510 ms and 432-550 ms) on days 2 and 3 with HCQ blood levels that varied widely (0.03 and 1.74 µg/mL, respectively) with no correlation to its QT effect. Nevertheless, in revoking the EUA for CQ and HCQ on 15 June 2020, the FDA determined that in light of ongoing serious cardiac adverse events and other potential serious side effects, the known and potential benefits of CQ and HCQ no longer outweigh the known and potential risks for the authorized use.53

The studies summarized in Table 3 show that at the doses used in QT-liability studies, typically HCQ 800 mg on day 1 followed by 400 mg daily for 4 days,70,71,72 a substantial proportion of patients developed QTc interval prolongation, many with absolute QTc interval exceeding the 500 ms threshold for likely proarrhythmia risk. However, the number of patients developing TdP or serious ventricular arrhythmias was very small. Of the total cohort of 673 patients across these five studies, 92 (13.9%) developed an absolute QTc interval exceeding 500 ms and yet, despite the presence of risk factors such as comorbidities and other QT-prolonging drugs, only 3 progressed to develop TdP. The low prevalence of proarrhythmia is also supported by a meta-analysis of 14 studies involving 1515 patients, showing that approximately 10% of COVID-19 patients treated with CQ or HCQ developed QT prolongation but ventricular arrhythmias were found in only two COVID-19 patients, both from a group of 28 treated with high-dose CQ.53 Jain et al67 also reported that although 19.7% of the 524 patients they screened had QT prolongation, none developed TdP despite the presence of multiple risk factors for proarrhythmia. Another study in 105 ethnic minority COVID-19 patients also reported an increase in the rates of QTc interval duration ≥500 ms from 4.8% baseline to 16.2% post-treatment with CQ/HCQ with or without AZM and yet only one patient developed non-fatal ventricular tachycardia.97 In this study, patients who had either QTc ≥ 500 ms or an increase in QTc of ≥60 ms had increased odds of mortality than those who did not, though no patients died from ventricular tachyarrhythmia; the high mortality is believed to be probably linked to the severity of viral disease requiring intubation in ICU.

A large retrospective study on the QT liability of HCQ in rheumatology patients treated with median dose of 400 mg daily for a median duration of 1006 days revealed that the mean QTc increased by a mean of only 8 ms from 4.8% baseline to 16.2% post-treatment with CQ/HCQ with or without AZM and yet only one patient developed non-fatal ventricular tachycardia.97 In this study, patients who had either QTc ≥ 500 ms or an increase in QTc of ≥60 ms had increased odds of mortality than those who did not, though no patients died from ventricular tachyarrhythmia; the high mortality is believed to be probably linked to the severity of viral disease requiring intubation in ICU.
comedication with QT-prolonging drugs (eg AZM) are obvious but it is also worth considering the extent to which HCQ-induced small increases in QTc interval are potentiated by increased levels of IL-6. Furthermore, there are also a number of explanations to account for low prevalence of proarrhythmia despite high frequency of proarrhythmic prolongation of QT interval. The data emphasize not only an imperfect correlation between the two but also raises the possibility of other poorly understood proarrhythmia-mitigating mechanisms in COVID-19 patients. The observed low frequency of ventricular tachyarrhythmias or TdP in COVID-19 patients receiving HCQ ± AZM, also reflects the success of monitoring strategies and timely discontinuation of therapy in patients who develop QT interval prolongation.

Completed clinical trials investigating HCQ efficacy have such limitations that it is by no means given that the risk outweighs the potential benefit of higher more appropriate doses of HCQ. The potential role of IL-6 in modifying cardiac repolarization also suggests that the risk in mild-to-moderate cases of COVID-19 may be small, if at all, and possibly greater in those with severe disease.\(^6,7,23\) Importantly, the risk can be well managed by careful monitoring of ECGs and other proarrhythmia risk factors and a number of authors have proposed monitoring strategies for COVID-19 patients during the clinical use of HCQ/AZM.\(^6,7,99-103\) Important factors to bear in mind when computing QT-related risk are the way QT interval is measured and then corrected for heart rate. All the five studies in Table 3 used Bazett’s correction. Following their study of the QT liability of HCQ/AZM in COVID patients, Bun et al\(^104\) reported an average ~20 ms difference between average baseline automated QTc and manual QT measurements (Bazett’s correction). The agreement was perfect when using Fridericia’s correction. One study in COVID-19 patients treated with CQ reported that CQ induced a mean prolongation of 75 ms for the computerized interpretation and 43 ms for the manually calculated QTc interval and that 19 of the 30 patients unnecessarily had their treatment prematurely discontinued or had their dose adjusted due to a prolonged QTc interval based on the computerized interpretation of the ECG.\(^105\) Thus, manually measured QT interval, corrected by Fridericia correction, may be the most appropriate to compute the potential risk of a proarrhythmia.

Davis et al\(^6\) identified 31 large registered randomized trials with a target sample size of at least 1000 participants, grouped into four categories (prophylaxis and treatment of outpatients with mild COVID-19 and treatments of hospitalized patients with moderate and moderate-to-severe COVID-19 disease). HCQ was the most common therapeutic agent studied in 24 of these 31 trials, with potential total sample size of over 25 000 participants. In the wake of the results from the RECOVERY trial, the current status on the use of HCQ in these and other ongoing trials is unknown.

5 | WHAT IS NEW AND CONCLUSIONS

It is questionable whether the ongoing clinical trials will shed any further helpful light on the safety, efficacy and risk/benefit of CQ and HCQ in combating COVID-19 infection. At the doses used, the findings from the therapeutic RECOVERY trial\(^25\) and the prophylaxis study by Boulware et al\(^15\) are not encouraging. On the balance of probability, unless higher doses are tested in ongoing trials, there appears little cause for optimism in repurposing either CQ or HCQ, with or without AZM, to fight COVID-19 pandemic. The resulting discontinuation of HCQ from major large studies effectively marks the end of repurposing CQ or HCQ for combating COVID-19 infection but doubts will linger as to whether the doses used hitherto had an optimal risk/benefit balance. Failure to determine an optimal therapeutic dose and risk/benefit balance has frustrated numerous previous attempts at repurposing old drugs.\(^1\)

**ORCID**

Rashmi R. Shah  \(<\text{https://orcid.org/0000-0002-8280-6467}>\)

**REFERENCES**

1. Shah RR, Stonier PD. Repurposing old drugs in oncology: opportunities with clinical and regulatory challenges ahead. J Clin Pharm Ther. 2019;44:6-22.
2. Langedijk J, Mantel-Teeuwisse AK, Slijkerman DS, Schutjens MH. Drug repositioning and repurposing: terminology and definitions in literature. Drug Discov Today. 2015;20:1027-1034.
3. Wong WW, Dimitroulakos J, Minden MD, Penn LZ. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia. 2002;16:508-519.
4. Ahn KS, Sethi G, Aggarwal BB. Reversal of chemoresistance and enhancement of apoptosis by statins through downregulation of the NF-κB pathway. Biochem Pharmacol. 2008;75:907-913.
5. Cho SJ, Kim JS, Kim JM, Lee JY, Jung HC, Song IS. Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice. Int J Cancer. 2008;123:951-957.
6. Kuoppala J, Lamminpää A, Pukkala E. Statins and cancer: a systematic review and meta-analysis. Eur J Cancer. 2008;44:2122-2132.
7. Mei Z, Liang M, Li L, Zhang Y, Wang Q, Yang W. Effects of statins on cancer mortality and progression: a systematic review and meta-analysis of 95 cohorts including 1,111,407 individuals. Int J Cancer. 2017;140:1068-1081.
8. Seckl MJ, Ottensmeier CH, Cullen M, et al. Multicenter, phase III, randomized, double-blind, placebo-controlled trial of pravastatin added to first-line standard chemotherapy in small-cell lung cancer (LUNGSTAR). J Clin Oncol. 2017;35:1506-1514.
9. Davis JS, Ferreira D, Denholm JT, Tong SYC. Clinical trials for the prevention and treatment of COVID-19: current state of play. Med J Aust. 2020;213:86-93.
10. Rolain J-M, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents. 2007;30:297-308.
11. Devaux CA, Rolain J-M, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020;55:105938.
12. Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nature Rev Rheumatol. 2020;16:155-166.
13. Tripathy S, Dassarma B, Roy S, Chabalala H, Matsabisa MG. A review on possible modes of actions of chloroquine/hydroxychloroquine: repurposing against SAR-COV-2 (COVID 19) pandemic. Int J Antimicrob Agents. 2020. https://doi.org/10.1016/j.ijantimicag.2020.106028
14. European Commission. Orphan Designation: Chloroquine for the Treatment of Gioma. Amsterdam, the Netherlands: European Medicines Agency (EU/3/14/1377) (19 November 2014).

15. Pareja-Coronel A. Treatment of viral hepatitis with chloroquine. Am J Gastroenterol. 1963;39:288-298.

16. Picot S, Marty A, Bienvenu A-L, et al. Coalition: advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19. One Health. 2020;9:100131.

17. Huang Z, Srinivasan S, Zhang J, et al. Discovering thiamine transporters as targets of chloroquine using a novel functional genomics strategy. PLoS Genet. 2012;8(11):e1003083. https://doi.org/10.1371/journal.pgen.1003083

18. Rodrigo C, Fernando SD, Rajapakse S. Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review. Clin Microbiol Infect. 2020;26(8):979-987.

19. Touret F, de Lamballerie X. Of chloroquine and COVID-19. Travel Med Infect Dis. 2020;177. https://doi.org/10.1016/j.tmaid.2020.104762

20. Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun. 2004;323:264-268.

21. Yang Q, Xie L, Zhang W, et al. Analysis of the clinical characteristics, drug treatments and prognoses of 136 patients with coronavirus disease 2019. J Clin Pharm Ther. 2020;45:609-616.

22. Harrigan JJ, Hubbard RA, Thomas S, et al. Association between US Administration endorsement of hydroxychloroquine for COVID-19 and outpatient prescribing. J Gen Intern Med. 2020. https://doi.org/10.1007/s11606-020-05938-4

23. Vaduganathan M, van Meijgaard J, Mehra MR, Joseph J, O’Donnell CJ, Warraich HJ. Prescription fill patterns for commonly used drugs during the COVID-19 pandemic in the United States. JAMA. 2020;323:2524-2526.

24. Gopinathnair R, Merchant FM, Lakkireddy DR, et al. COVID-19 and cardiac arrhythmias: a global perspective on arrhythmia characteristics and management strategies. J Interv Card Electrophysiol. 2020. https://doi.org/10.1007/s10840-020-00789-9

25. McChesney EW. Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate. Am J Med. 1983;75:11-18.

26. Finbloom DS, Silver K, Newsome DA, Gunkel R. Comparison of hydroxychloroquine and chloroquine use and the development of retinal toxicity. J Rheumatol. 1985;12:692-694.

27. Paní A, Lauriola M, Romandini A, Scaglione F. Macrolides and viral infections: focus on azithromycin in COVID-19 pathology. Int J Antimicrob Agents. 2020;56(2):106053.

28. Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients hospitalised for COVID-19: an open-label, randomized, controlled trial. Travel Med Infect Dis. 2020;369:m1844.

29. Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial. BMJ. 2020;369:m1849.

30. Voss A. Official statement from International Society of Antimicrobial Chemotherapy (ISAC). Int J Antimicrob Agents. 2020;3. https://www.isac.world/news-and-publications/official-isac-statement. Accessed July 18, 2020.

31. Anon. FDA grants Emergency Use Authorization for Chloroquine and Hydroxychloroquine. Silver Spring, MD: Food and Drug Administration. 2020. https://www.fda.gov/media/136537/download. Accessed May 15, 2020.

32. SOLIDARITY: An international randomised controlled trial to evaluate non-licensed COVID-19 treatments in addition to standard care among hospitalised patients. https://www.trialsitenews.com/who-launches-global-megatrial-of-the-four-most-promising-coronavirus-treatments/. Accessed July 18, 2020.

33. DISCOVERY: Trial of treatments for COVID-19 in hospitalized adults (DisCoVeRy). EU Clinical Trials Register: 2020-000936-23.
COVID-19: a multinational registry analysis. Lancet. 2020. https://doi.org/10.1016/S0140-6736(20)31180-6

51. Mehra MR, Ruschitzka F, Patel AN. RETRACTION—hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020;395(10240):1820.

52. RECOVERY trial: statement from the chief investigator. 2020. https://www.recoverytrial.net/files/hcq-recovery-statement-050620-final-002.pdf. Accessed July 18, 2020.

53. Anon. FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine. Silver Spring, MD: Food and Drug Administration. 2020. https://www.fda.gov/media/138945/.

54. Anon. FDA drug label for PLAQUENIL (hydroxychloroquine sulfate). https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/009768Orig1s051lbl.pdf. Accessed July 18, 2020.

55. Ren L, Xu W, Overton JL, Yu S, Chiamvimonvat N, Thai PN. Assessment of hydroxychloroquine and chloroquine safety profiles—a systematic review and meta-analysis. medRxiv. https://doi.org/10.10110.2020.05.02.20088872

56. Grandvaux B, Fresse A, Cholle C, Yamani S, Dautriache A. Dautriache A for French network of regional pharmacovigilance centres. Adverse drug reactions of hydroxychloroquine: analysis of French pre-pandemic SARS-CoV-2 pharmacovigilance data. Therapies. 2020;75(4):385-387.

57. Wang G, Lu C-J, Trafford AW, et al. Mechanistic insights into ventricular arrhythmogenesis of hydroxychloroquine and azithromycin for the treatment of COVID-19. bioRxiv. 2020. https://doi.org/10.1101/2020.05.21.108605

58. Yang Z, Prinsen JK, Bersell KR, et al. Azithromycin causes a novel proarhythmic syndrome. Circ Arrhythm Electrophysiol. 2017;10:e003560.

59. Anon. FDA drug label for ARALEN (chloroquine phosphate). https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/006002s045lbl.pdf. Accessed July 18, 2020.

60. Anon. FDA drug label for PLAQUENIL (hydroxychloroquine sulfate). https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/009768Orig1s051lbl.pdf. Accessed July 18, 2020.

61. Anon. FDA drug label for ZITHROMAX (azithromycin). https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/050710s049,050711s047,050784s034lbl.pdf. Accessed July 18, 2020.

62. Hancox JC, Hasnain M, Vieweg WVR, Breden Crouse EL, Baranchuk A. Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: a narrative review based on the study of case reports. Ther Adv Infect Dis. 2013;1:155-165.

63. Jankelson L, Karam G, Becker ML, Chinizat LA, Tsai M-C. QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review. Heart Rhythm. 2020. https://doi.org/10.1016/j.hrthm.2020.05.008

64. Gérard A, Romani S, Fresse A, et al. “Off-label” use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: a survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers. Therapies. 2020;75(4):371-379.

65. Anon. COVID-19: Reminder of Risk of Serious Side Effects with Chloroquine and Hydroxychloroquine. Amsterdam, the Netherlands: European Medicines Agency. 2020. https://www.ema.europa.eu/en/news/chloroquine-hydroxychloroquine-risk.

66. Anon. FDA Cautions Against Use of Hydroxychloroquine or Chloroquine for COVID-19 Outside of the Hospital Setting or a Clinical Trial Due to Risk of Heart Rhythm Problems. Silver Spring, MD: Food and Drug Administration. 2020. https://www.fda.gov/drugs/drug-safety-and-availability/2020-drug-safety-communications. Accessed July 18, 2020.

67. Jain S, Workman V, Ganeshan R, et al. Enhanced ECG monitoring of COVID-19 patients. Heart Rhythm. 2020. https://doi.org/10.1016/j.hrthm.2020.04.047

68. Borba MGS, Val FFA, Sampaio VS, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open. 2020;3:e208857.

69. van den Broek MPH, Möhlmann JE, Abelin BGS, Liebregts M, van Dijk VF, van de Garde EMW. Chloroquine-induced QTc prolongation in COVID-19 patients. Neth Heart J. 2020;28(7-8):406-409.

70. Saleh M, Gabriels J, Chang D, et al. The effect of chloroquine, hydroxychloroquine and azithromycin on the corrected QT interval in patients with SARS-CoV-2 infection. Circ Arrhythmia Electrophysiol. 2020. https://doi.org/10.1161/CIRCEP.120.008662

71. Chorin E, Wadhwa L, Magnani S, et al. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin. Heart Rhythm. 2020. https://doi.org/10.1016/j.hrthm.2020.05.014

72. Bessière F, Roccia H, Delinière A, et al. Assessment of QT intervals in a case series of patients with Coronavirus disease 2019 (COVID-19) infection treated with hydroxychloroquine alone or in combination with azithromycin in an intensive care unit. JAMA Cardiol. 2020:e201787. https://doi.org/10.1001/jamacardio.2020.1787

73. Mercuro NJ, Yen CF, Shim DJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for Coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020. https://doi.org/10.1001/jamacardio.2020.1834

74. Maraj I, Hummel JP, Taoulet R, et al. Incidence and determinants of QT interval prolongation in COVID-19 patients treated with hydroxychloroquine and azithromycin. J Cardiovasc Electrophysiol. 2020;31(8):1904-1907.

75. Gubernatorova EO, Gorshkova EA, Polinova AI, Drutskaya MD. IL-6: relevance for immunopathology of SARS-CoV-2. Cytokine Growth Factor Rev. 2020;53:13-24.

76. Coomes EA, Haghbayan H. Interleukin-6 in COVID-19: a systematic review and meta-analysis. medRxiv. 2020. https://doi.org/10.10110.2020.03.20048058

77. Zhu H, Rhee J-W, Cheng P, et al. Cardiovascular complications in patients with COVID-19: consequences of viral toxicities and host immune response. Curr Cardiol Rep. 2020;22:32.

78. Aromolaran AS, Srivastava U, Ali A, et al. Interleukin-6 inhibition of hERG underlies risk for acquired long QT in cardiac and systemic inflammation. PLoS One. 2018;13:e0208321.

79. Adlan AM, Panoulas VF, Smith JP, Fisher JP, Kitas GD. Association between corrected QT interval and inflammatory cytokines in rheumatoid arthritis. J Rheumatol. 2015;42:421-428.

80. Kobeysahi Y, Kobayashi Y, Yokoe I, et al. Heart rate-corrected QT interval duration in rheumatoid arthritis and its reduction with treatment with the interleukin 6 inhibitor tocilizumab. J Rheumatol. 2018;45:1620-1627.

81. Lackneri PE, Laghi-Pasini F, Bertolozzi I, et al. Systemic inflammation as a novel QT-prolonging risk factor in patients with torsades de pointes. Heart. 2017;103:1821-1829.

82. Perinel S, Launay M, Botelho-Nevers E, et al. Towards optimization of hydroxychloroquine dosing in intensive care unit COVID-19 patients. Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa394

83. Kang JE, Rhie SJ. Practice considerations on the use of investigational anti-COVID-19 medications: dosage, administration and monitoring. J Clin Pharm Ther. 2020. https://doi.org/10.1111/jcpt.13199

84. Desai A, Gyawali B. Endpoints used in phase III randomized controlled trials of treatment options for COVID-19. eClin Med. 2020;23:100403.
85. Bienvenu A-L, Marty AM, Jones MK, Picot S. Systematic review of registered trials of Hydroxychloroquine prophylaxis for COVID-19 health-care workers at the first three of 2020. One Health. 2020;10:100141.

86. Galvis V, Spinelli FR, Tello A, et al. Hydroxychloroquine as prophylaxis for Coronavirus SARS-CoV-2 infection: review of the ongoing clinical trials. Arch Bronconeumol. 2020. https://doi.org/10.1016/j.arbres.2020.05.008

87. Lu L, Li F, Wen H, et al. An evidence mapping and analysis of registered COVID-19 clinical trials in China. BMC Med. 2020;18:167.

88. Zhu R-F, Gao Y-L, Robert S-H, et al. Systematic review of the registered clinical trials of Coronavirus diseases 2019 (COVID-19). medRxiv. 2020. https://doi.org/10.1101/2020.03.01.20029611

89. Mathian M, Mahevas M, Rohmer J, et al. Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. Ann Rheum Dis. 2020;79:837-839.

90. Konig MF, Kim AH, Scheetz MH, et al. Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19. Ann Rheum Dis. 2020. https://doi.org/10.1136/annrheumdis-2020-217690

91. Favalli EG, Gerosa M, Murgo A, et al. Are patients with systemic lupus erythematosus at increased risk for COVID-19? Ann Rheum Dis. 2020. https://doi.org/10.1136/annrheumdis-2020-217787

92. Cassione EB, Zanframundo G, Biglia A, Codullo V, Montecucco C, Cavagna L. COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine. Ann Rheum Dis. 2020. https://doi.org/10.1136/annrheumdis-2020-217717

93. Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020;71(15):732-739.

94. Garcia-Cremades M, Solans BP, Hughes E, et al. Optimizing hydroxychloroquine dosing for patients with COVID-19: an integrative modeling approach for effective drug repurposing. Clin Pharmacol Ther. 2020;108(2):253-263.

95. Al-Kofahi M, Jacobson P, Boulware DR, et al. Finding the dose for hydroxychloroquine prophylaxis for COVID-19: the desperate search for effectiveness. Clin Pharmacol Ther. 2020. https://doi.org/10.1002/cpt.1874

96. Al-Kofahi M, Jacobson P, Boulware DR, et al. Finding the dose for hydroxychloroquine prophylaxis for COVID-19: the desperate search for effectiveness. Clin Pharmacol Ther. 2020. https://doi.org/10.1002/cpt.13267

97. Hsie BC, Greige N, Quiroz JA, et al. QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin. J Interv Card Electrophysiol. 2020. https://doi.org/10.1007/s10840-020-00822-x

98. Hooks M, Bart B, Vardeny O, Westman A, Adabag S. Effects of hydroxychloroquine treatment on QT interval. Heart Rhythm. 2020. https://doi.org/10.1016/j.hrthm.2020.06.029

99. Giudicesi JR, Noseworthy PA, Friedman PA, Ackerman MJ. Urgent guidance for navigating the QTc-prolonging and torsadogenic potential of possible pharmacotherapies for COVID-19. J Mayo Clin Proc. 2020. https://doi.org/10.1016/j.mayocp.2020.03.024

100. Mitra RL, Greenstein SA, Epstein LM. An algorithm for managing QT prolongation in coronavirus disease 2019 (COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin: possible benefits of intravenous lidocaine. Heart Rhythm Case Rep. 2020;6(5):244-248.

101. Sapp JL, Alqarawi W, MacIntyre CJ, et al. Guidance on minimizing risk of drug-induced ventricular arrhythmia during treatment of COVID-19: a statement from the Canadian Heart Rhythm Society. Can J Cardiol. 2020;36:948-951.

102. Naksuk N, Lazar S, Peeraphatdit TB. Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol. Eur Heart J. 2020;9(3):215-221.

103. Carron J, Sharif Z, Hussein H, Kennedy M, McAdam B, Sheahan R. Clinical guidance for navigating the QTc prolonging and arrhythmogenic potential of pharmacotherapy during the COVID-19 pandemic. Ir J Med Sci. 2020. https://doi.org/10.1016/j.s1184-5-020-02291-7

104. Bun S-S, Taghji P, Courjon J, et al. QT interval prolongation under hydroxychloroquine/azithromycin association for inpatients with SARS-CoV-2 lower respiratory tract infection. Clin Pharmacol Ther. 2020. https://doi.org/10.1002/cpt.1968

105. Sinkeler FS, Berger FA, Muntingha JJ, Jansen MMPM. The risk of QTc-interval prolongation in COVID-19 patients treated with chloroquine. Neth Heart J. 2020;28(7-8):418-423.

How to cite this article: Shah RR. Chloroquine and hydroxychloroquine for COVID-19: Perspectives on their failure in repurposing. J Clin Pharm Ther. 2021;46:17–27. https://doi.org/10.1111/jcpt.13267